K. J. Seok

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

M. Dimopoulos, K. Konstantopoulos, M. Mohty, 2021, The Lancet.